Home › Burkitt Lymphoma › Ohio › Cincinnati
Pag-aaral pangklinika para sa Burkitt Lymphoma sa Cincinnati, OH
Isang pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cincinnati. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Nagre-recruitPhase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi ang layo
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Nagre-recruitPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Nagre-recruitPhase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Nagre-recruitPhase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi ang layo
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Nagre-recruitPhase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Nagre-recruitPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Nagre-recruitPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Nagre-recruitPhase 1
- University of Cincinnati, Cincinnati
Pag-aaral para sa Burkitt Lymphoma sa ibang lungsod
- Houston, TX21 pag-aaral
- Milwaukee, WI16 pag-aaral
- Philadelphia, PA16 pag-aaral
- New York City, NY14 pag-aaral
- Chicago, IL13 pag-aaral
- Seattle, WA12 pag-aaral
- Atlanta, GA11 pag-aaral
- Boston, MA10 pag-aaral
- Los Angeles, CA10 pag-aaral
- Durham, NC10 pag-aaral
- Aurora, CO10 pag-aaral
- Kansas City, MO10 pag-aaral
Iba pang pag-aaral sa Cincinnati
- Non-Small Cell Lung Cancer35 pag-aaral
- Kanser (lahat ng uri)28 pag-aaral
- Kanser sa Suso25 pag-aaral
- Pagkabigo ng Puso24 pag-aaral
- Colorectal Cancer21 pag-aaral
- Metastatic Cancer20 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
- Kanser sa Baga19 pag-aaral
- Kanser sa Ovary19 pag-aaral
- Obesity19 pag-aaral
- Kanser sa Prostate18 pag-aaral
- Multiple Myeloma17 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.